Amperometric Biosensing of miRNA-21 in Serum and Cancer Cells at Nanostructured Platforms Using Anti-DNA–RNA Hybrid Antibodies

Mohamed Zouari,†‡ Susana Campuzano,§ José M. Pingarrón,*,⊥∥ and Noureddine Raouafi*†

1Sensors and Biosensors Group, Laboratory of Analytical Chemistry and Electrochemistry (LR99ES15), Department of Chemistry, Faculty of Sciences, University of Tunis El Manar, Rue Béchir Salem Belkheria, Tunis El-Manar, 2092 Tunis, Tunisia
2Institut Pasteur de Tunis, 13 Place Pasteur, 1002 Tunis, Tunisia
3Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
4IMDEA Nanoscience, Ciudad Universitaria de Cantoblanco, 28049 Madrid, Spain

ABSTRACT: This paper describes a disposable amperometric biosensor for simple and sensitive determination of miRNA-21. The bioplatform consists of gold nanoparticles-nanostructured electrode surfaces on which a direct hybridization assay involving the immobilization of a specific thiolated DNA capture probe and recognition of the formed DNA–miRNA-21 heteroduplex by a specific antibody is implemented. The antibody is further recognized through its Fc region by a commercial bacterial protein containing 40 units of horseradish peroxidase (HRP) (ProtA-polyHRP40). The amperometric detection of the hybridization process using the H2O2/hydroquinone system allows quantification of the target miRNA in the 0.096–25 pM linear range with a detection limit of 29 fM (0.29 amol in 10 μL of sample). The bioplatform offers excellent selectivity against noncomplementary sequences and very acceptable against sequences with an unpaired base (only 30% of the response obtained for the target miRNA). In addition, the bioplatform was shown to be useful for the determination of the endogenous content of the target oncomiR directly in blood serum from breast cancer patients and in breast cancer cells using only 10 ng of total extracted RNA.

1. INTRODUCTION

Nanostructured electrodes with gold nanoparticles (AuNPs) have demonstrated unique properties in the development of nucleic acid electrochemical biosensors with improved analytical performances. The catalytic activity of the AuNPs together with their large surface area and excellent biocompatibility make these nanostructured surfaces more conductive and allow the immobilization of large probe loadings with optimal orientation and spacing for efficient hybridization, keeping their biological activity and storage stability.1−6 The resulting bioplatforms exhibit also interesting advantages in terms of simplicity, cost, assay time, and applicability in different environments. These characteristics make AuNPs-involved bioplatforms especially attractive compared to conventional methodologies for their implementation in routine determinations.8

These properties have been successfully harnessed to develop electrochemical platforms for the determination of biomarkers of high clinical relevance, such as miRNAs,5,6 a class of endogenous and small noncoding RNAs that play a relevant role in many diseases, particularly in human cancers.7,8 Alterations in miRNA expression levels are involved in the initiation and progression of human cancers, and minimal signature profiles have been identified for various types of human cancers, where miRNAs can be regulated both upward and downward. Therefore, the determination of regulatory patterns is of great importance since they can provide relevant information about tumor initiation, invasion, and metastasis processes.

However, the determination of miRNAs is highly complex due to their short sequence, low concentration level, and high sequence similarity between members of the same family. Conventional available methods for miRNAs determination, such as northern blotting,9,10 in situ hybridization, reverse transcription polymerase chain reaction,11−13 and miRNA microarrays14−17 suffer from important limitations (use in centralized laboratories, expensive, laborious, require specialized personnel, and poorly portable instrumentation), which make the development of more simple and rapid alternative strategies highly desirable.

In recent years, several electrochemical platforms have been reported for the single or simultaneous determination of miRNAs either using integrated formats5,8−18 or involving magnetic beads (MBs).23−27 However, many of these biosensors require amplification strategies, which demand complex and/or long protocols to achieve the required sensitivity. This is an important restriction for their wide use in clinical practice by unskilled personnel. In this context, particularly attractive and relatively simple electrochemical strategies have been reported recently with acceptable...
sensitivity using commercial capture and detector bioreceptors with high affinity toward RNA homohybrids (viral protein p19) and heterohybrids (anti-DNA–RNA hybrid antibodies)19–21,23,25,26). This paper describes a novel electrochemical bioplatform for miRNAs determination, which combines the simplicity of a direct DNA–RNA hybridization format with the advantages of disposable AuNPs-nanostructured platforms and the high specificity and affinity of anti-DNA–RNA hybrid antibodies. To achieve high sensitivity, an easily implementable amplification strategy using a multienzyme bacterial protein able to recognize the Fc region of the anti-DNA–RNA hybrid antibody is used. The hybridization reaction is monitored amperometrically with the H2O2/hydroquinone (HQ) system. The resulting biosensor exhibits interesting performance in terms of sensitivity, selectivity, and reduced fabrication and assay times. It was successfully applied for the reliable and accurate determination of the selected target miRNA-21 (a relevant onco-miRNA32) directly in a five-times diluted human blood serum from breast cancer patients as well as in breast cancer cells using the lowest amount of total extracted RNA reported to date for an electrochemical biosensor.

2. RESULTS AND DISCUSSION
The developed strategy is displayed in Scheme 1. It involves direct RNA–DNA hybridization implemented on disposable carbon surfaces nanostructured with AuNPs. The target miRNA was selectively captured on the nanostructured surfaces by efficient hybridization with a complementary thiolated DNA probe. The resulting biosensor exhibits interesting performance in terms of sensitivity, selectivity, and reduced fabrication and assay times. It was successfully applied for the reliable and accurate determination of the selected target miRNA-21 (a relevant onco-miRNA32) directly in a five-times diluted human blood serum from breast cancer patients as well as in breast cancer cells using the lowest amount of total extracted RNA reported to date for an electrochemical biosensor.

Scheme 1. Schematic Display of the Biosensor Developed with AuNPs/Screen-Printed Carbon Based Electrodes (SPCEs) for the Amperometric Determination of miRNA-21 Involving a Specific HS-DNA Probe, Direct DNA/miRNA Hybridization, And the Use of Anti-DNA–RNA Antibody As Detection Bioreceptor Further Labeled with ProtA-PolyHRP40.

Figure 1. Amperometric responses obtained in the absence and presence of 20 pM synthetic miRNA-21 at AuNPs/SPCEs with and without immobilized HS-DNA probe (a) and in the presence of 20 pM miRNA-21 at AuNPs/SPCEs modified with HS-DNA or HS-RNA probes complementary to miRNA-21 (b).
Figure 1 shows the comparison of the amperometric traces recorded in the absence and presence of the target miRNA at unmodified AuNPs/SPCEs and modified with HS-DNA and HS-RNA capture probes. Negligible and similar amperometric responses were observed in the absence of miRNA-21 on HS-DNA/AuNPs/SPCEs and in the presence of 20 pM miRNA-21 on AuNPs/SPCEs with no immobilized HS-DNA capture probe immobilized and on complementary HS-RNA/AuNPs/SPCEs (Figure 1b). These results confirmed that the amperometric responses were due to the efficient hybridization of the HS-DNA capture probe with the target miRNA, the negligible nonspecific adsorption of anti-DNA–RNA hybrid antibody and ProtA-polyHRP40 on the AuNPs/SPCEs surface, and the specificity of the antibody for the selective detection of DNA–RNA heterohybrids.\(^{33-35}\)

2.1. Optimization of the Experimental Variables. The most relevant experimental variables affecting the behavior of the designed bioelectrode were optimized. The current measured in the presence of 20 pM (signal, S) and in the absence (noise, N) of the target miRNA-21 as well as the corresponding ratio (S/N ratio) were used as selection criteria. The results obtained are shown in Figure 2 and summarized in Table 1. Apart from these, other variables used involved in the modification of AuNPs/SPCEs, such as the HS-DNA probe concentration, the hybridization time with the target miRNA\(^4,22\), the pH value, the detection potential, and the concentrations of H\(_2\)O\(_2\) and HQ, were taken from previous works.\(^{36-38}\)

![Figure 1](image1.png)

![Figure 2](image2.png)

Table 1. Evaluation of Different Experimental Variables Involved in the Preparation and Functioning of the Developed Biosensor

| variable                                      | evaluated range | optimal value selected |
|-----------------------------------------------|-----------------|------------------------|
| anti-DNA–RNA hybrid antibody (dilution)       | 1/5000–1/250    | 1/1000                 |
| ProtA-polyHRP40 (dilution)                    | 1/500–1/5       | 1/50                   |
| incubation time with mixture DNA–RNA hybrid antibody + ProtA-polyHRP40 (min) | 0–90            | 60                     |
| number of steps\(^a\)                         | 1–3             | 2                      |

\(^a\)Starting from the preparation of HS-DNA/AuNPs/SPCEs.

Figure 2a,b shows the effect of the concentration of bioreagents used to carry out the heterohybrid recognition and the enzymatic labeling on the biosensor response. The 1/1000 and 1/50 dilutions of the anti-DNA–RNA hybrid antibody and ProtA-polyHRP40 conjugate provided larger S/N ratios, and therefore, they were selected for further work.

In an attempt to simplify the whole working protocol and reduce the assay time, the influence of the number of steps involved in the preparation of the biosensor on its analytical behavior was checked; 30 min incubation steps were assayed in all cases starting from the preparation of HS-DNA/AuNPs/SPCEs. Figure 2c shows a comparison between the results obtained with the following working protocols:

---

ACM Omega, 2018, 3, 8923–8931

DOI: 10.1021/acsomega.8b00986
• One single incubation step with a mixture solution consisting of the target miRNA, anti-DNA–RNA antibody, and ProtA-polyHRP40.
• Two successive incubation steps: first with the target miRNA and thereafter with a mixture solution containing anti-DNA–RNA antibody and ProtA-polyHRP40.
• Three successive incubation steps with the target miRNA, anti-DNA–RNA antibody, and ProtA-polyHRP40.

Figure 2c shows clearly that the protocol involving two successive incubation steps provided a larger S/N current ratio. These results suggest that the mixing of all of the bioreagents worsened the efficiency of the hybridization process, whereas the anti-DNA–RNA antibody was better recognized by ProtA-polyHRP40 when both reagents were incubated in homogeneous solution. Once the optimal working protocol was selected, the influence of the incubation time with the mixture of anti-DNA–RNA antibody and ProtA-polyHRP40 to label the DNA/miRNA heteroduplex captured on the electrode was evaluated. As it is shown in Figure 2d, there were no significant differences for the nonspecific responses, but the specific current increased notably with the incubation time up to 60 min. Accordingly, this incubation time ensured an efficient labeling of the immobilized heterohybrids and was selected for further studies.

2.2. Analytical Characteristics. Figure 3 shows the amperometric responses obtained for different concentrations of the synthetic target miRNA-21. Inset: calibration plot. The error bars are estimated as triple of the standard deviation of three replicates.

Figure 3. Amperometric traces obtained with the resulting HS-DNA/AuNPs/SPCE biosensors for different concentrations of the synthetic target miRNA-21. Inset: calibration plot. The error bars are estimated as triple of the standard deviation of three replicates.

The reproducibility of the measurements carried out with the developed bioplatform was checked by comparing the currents obtained for 1 pM miRNA-21 with nine different biosensors prepared in the same manner. A relative standard deviation value of 2.9% was calculated to show an excellent reproducibility in both the biosensor preparation and amperometric measurement procedures.

Regarding the storage stability of the bioplatforms, the currents measured with HS-DNA/AuNPs/SPCEs, which were stored at 4 °C in a humidified chamber (after incubation with 1% (w/v) bovine serum albumin (BSA)), for 0 and 1.0 pM miRNA-21 showed that they remained within the set control limits over a 2 month period (no longer times were tested) (Figure 4). This attractive storage stability, in good agreement with the behavior observed for bioelectrodes involving thiolated RNA probes at disposable AuNP-nanostructured scaffolds,4,22 is attributed to the great biocompatibility and major role played by AuNPs in keeping the activity of the biomolecules immobilized onto their surface.

2.3. Selectivity. Due to the high sequence homology between miRNA family members, a very important feature of miRNAs biosensing platforms is the selectivity toward other nontarget and mismatched miRNA sequences. Figure 5 displays amperometric traces provided by the HS-DNA/AuNPs/SPCEs in the absence and presence of the synthetic target miRNA, a single-central base mismatched (1-m) and a non-matched miRNA. The resulting LOD was 29 fM (0.29 amol in 10 μL sample).
Table 2. Analytical Characteristics of Electrochemical Biosensors Reported so far for miRNAs Determination Using DNA–RNA Hybrid Antibodies

| electrode                  | role of DNA–RNA hybrid antibody | electrochemical technique | target miRNA          | LL                  | LOD      | selectivity against 1-m sequences (%) | biosensor or MBs fabrication/assay time (h) | sample (amount) | ref |
|----------------------------|---------------------------------|---------------------------|------------------------|----------------------|----------|--------------------------------------|---------------------------------------------|-----------------|-----|
| carbon paper/reduced graphene oxide (RGO)/GCE | detector                        | SWV                       | miRNA-29b-1 and miRNA-141 | 1–1 × 10⁶ Fm          | 8 Fm     | 12 h/2 h 30 min                       | 19                           |                 |     |
| oxidized multiwalled carbon nanotubes/RGO/GSPEs | detector                        | SWV                       | miRNA-29b-1 and miRNA-141 | 10–1 × 10⁶ ΩM         | 10 ΩM    | 12 h/2 h 30 min                       | 20                           |                 |     |
| SPCE                      | capture bioreceptor immobilized onto ProtG-MBs | amperometry (H₂O₂/HQ) | miRNA-21 and miRNA-205      | (8.2–250) × 10⁵ ΩM | 2.4 × 10³ ΩM (60 amol) | 51 | 45 min/2 h | RNA extracted from cancer cells (500 ng) and human tumor tissues (1000 ng) | 23 |
| SPCE                      | detector bioreceptor for DNA–RNA heterohybrid immobilized onto Strep-MBs | amperometry (H₂O₂/HQ) | miRNA-21          | (1.0–100) × 10³ ΩM | 0.4 × 10³ ΩM (10 amol) | 48 | 30 min/1.5 h | RNA extracted from cancer cells (250 ng) and human tumor tissues (250 ng) | 26 |
| AuNPs/GCE                  | detector                        | DPV                       | miRNA-319a          | 0.5–500 ΩM         | 0.40 ΩM    | 14 | 13 h/5 h 10 min | RNA extracted from rice seedlings (50 ng) | 21 |
| AuNPs/SPCE                 | detector bioreceptor            | amperometry (H₂O₂/HQ) | miRNA-21          | (0.96–2.5) × 10³ ΩM | 29 ΩM (0.29 amol) | 30 | 9 h/1 h 30 min | this work | |

“Once modified the electrode or the MBs with the capture bioreceptor. b% of the response obtained in comparison to that of the target miRNA.
suitability of the developed methodology was tested by determining the endogenous content of miRNA-21 directly in blood serum from breast cancer patients and in raw RNA, extracted from breast cancer cells.

Figure 6a shows the amperometric traces recorded with the developed biosensors for the three serum samples analyzed (one from a healthy individual and two from patients diagnosed with breast cancer). The samples were five-times diluted and heated, as described in Section 4.6. These results are in agreement with those reported by other authors showing that miRNA-21 expression is about 3–4 times larger in breast cancer patients that in healthy individuals using an indirect highly liquid chromatography—mass spectrometry (MS)/MS method. No significant differences were found for the slope values of the calibration plot constructed with miRNA-21 standards (Figure 3, 378 ± 7 nA pM⁻¹) and of the calibration graphs constructed for five-times diluted and heated sera from the healthy individual (374 ± 8 nA pM⁻¹) and the breast cancer patients 353 ± 8 nA pM⁻¹ spiked with growing amounts of synthetic miRNA-21 up to 20 pM. This made the determination of the endogenous concentration of the target miRNA in serum feasible by simple interpolation of the Δi values measured for the diluted samples into the miRNA standards calibration plot. The concentrations of miRNA-21 obtained were 2.0 ± 0.2, 8.0 ± 0.3, and 7.3 ± 0.4 pM in the serum samples from the healthy individual and breast cancer patients 1 and 2, respectively.

Regarding the determination of miRNA-21 in cellular extracted RNA. Figure 6b shows the amperometric traces provided by the HS-DNA/AuNPs/SPCEs showing the expected miRNA-21 3–4 times higher expression in the tumorigenic (MCF-7) compared to the nontumorigenic (MCF-10A) cells according to the oncogenic role of this miRNA. Similar to that observed in diluted and heated serum samples, no statistically significant differences were found between the slope values of the corresponding calibration plots constructed with the synthetic target miRNA-21 both in buffered solutions and in the presence of 10 ng of RNA, extracted from MCF-10A and MCF-7 cells 354 ± 9 nA pM⁻¹, thus confirming the absence of apparent matrix effect in the cellular RNA, analysis. Interpolation in the miRNA-21 standard calibration plot provided concentrations of 0.82 ± 1.05 and 2.97 ± 3.22 amol ng⁻¹ RNA, in MCF-10A and MCF-7 cells, respectively. These results are in complete agreement with those reported previously with concentrations ranging from 0.8 to 1.0 amol ng⁻¹ RNA, in MCF-10A and from 2.3 to 3.3 amol ng⁻¹ RNA, in MCF-7 cells. These results demonstrate the bioplatform usefulness for the accurate and selective determination of the target miRNA in the presence of many other nontarget miRNAs. Importantly, this determination can be accomplished using the lowest amount of raw RNA, reported so far with electrochemical biosensors, which required between 50 and 1000 ng of RNA, extracted from cells to perform the target miRNA determination.

3. CONCLUSIONS

This work reports a novel amperometric bioplatform to determine miRNA-21. Combining the inherent advantages of disposable surfaces nanostructured with gold nanoparticles with the use of selective antibodies to DNA–RNA heteroduplexes and bacterial immunoglobulin-binding protein conjugated to multiple HRP units made this determination possible with an LOD as low as 29 fM and good discrimination toward sequences with a single unpaired base. Interestingly, this bioplatform is able to accurately determine the endogenous content of miRNA-21 directly in human blood serum from breast cancer patients and in breast cancer cells using very small amount of RNA. It should be emphasized that no target miRNA amplification steps are required with this strategy. In addition, all of the reagents and disposable electrodes used are commercially available, making this bioscaffold particularly attractive to be handled by non-specialized personnel and even on an outpatient basis for routine determinations.

4. EXPERIMENTAL SECTION

4.1. Apparatus and Electrodes. Amperometric measurements were performed with a Metrohm Autolab PGSTAT M204 electrochemical workstation using Nova v1.11 software. The transducers, purchased from Dropens S.L. (Oviedo, Spain), were AuNP-modified screen-printed carbon electrodes (ref DRP-110GNP) consisting of a 4 mm diameter working electrode, a carbon counter electrode, and a Ag pseudoreference electrode and the specific cable connector with the potentiostat (ref DRP-CAC). Scanning electron microscopy (SEM) characterization studies carried out both by us and by the electrode supplier company confirm the presence of
AuNPs homogeneously distributed over the whole surface with a mean diameter of 30 nm.

A Bunsen AGT-9 Vortex, a Raypa steam sterilizer, a Telstar Biostar biological safety cabinet, an Optiv IYven system incubator shaker (Comecta S.A., Sharlab), and a NanoDrop ND-1000 spectrophotometer were employed.

4.2. Reagents and Solutions. Highest available grade reagents were used. NaH2PO4, Na2HPO4, NaCl, and KCl were purchased from Scharlab. Tris-(hydroxymethyl)aminomethane hydrochloride (Tris–HCl), mercaptotethanol (MCH), hydroquinone, H2O2 (30%, w/v), ethylenediaminetetraacetic acid (EDTA), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (Germany).

ProtA-polyHRP40, a native ProtA labeled with a homopolymer containing 40 HRP molecules (antibodies-online), and an anti-DNA–RNA hybrid antibody (AbS9.6) from Kerafast (Boston, MA) were commercially available. A commercial blocker solution, consisting of a phosphate-buffered saline (PBS) containing 1% w/v purified casein, from Thermo Scientific (Waltham, MA) was also used.

The buffer solutions were prepared with Milli-Q water (18 MΩ cm at 25 °C) and sterilized after their preparation to avoid RNase degradation. Phosphate-buffered saline (PBS) consisted of 0.01 M phosphate-buffered solution containing 137 mM NaCl and 2.7 mM KCl (pH 7.5), Tris–EDTA buffer (pH 8.0) formed by mixing 10 mM Tris–HCl, 1 mM EDTA, and 0.3 M NaCl (pH 8.0), and phosphate buffer (0.05 M, pH 6.0) were used.

The synthetic oligonucleotides used (sequences shown in Table 3) were purchased from Sigma-Aldrich (Germany).

Once received, they were reconstituted in nuclease-free water and dried with nitrogen. To prevent miRNA degradation by RNases, all manipulations, except the amperometric measurements, were made in a laminar flow cabinet.

4.5. Amperometric Detection. Amperometric detection at an applied potential of −0.20 V versus Ag pseudoreference electrode was carried out in stirred solutions by immersing the prepared bioelectrodes into an electrochemical cell containing 10 mL of 0.05 M phosphate buffer (pH 6.0) and freshly prepared 1.0 mM H2O2. Once the background current was stabilized, 50 μL of a 0.1 M H2O2 solution was added and the current was recorded for about 100 s until reaching the steady-state current. The Δi values given corresponded to the difference between the currents measured in the presence and absence of the target miRNA and are the average of three replicates (α = 0.05).

4.6. Application for the Analysis of Serum and Breast Cells-Extracted RNA. The developed bioplatform was used for the determination of the endogenous miRNA-21 content directly in human serum samples (without previous RNA extraction) and in RNA extracted from epithelial non-tumorigenic and tumorigenic breast cells. Blood serum samples were provided by Prof. Besma Loueslati (Department of Biology, University of Tunis El Manar) and collected from informed consenting patients according to ethical guidelines. Serum samples corresponded to healthy individuals and breast cancer patients. A serum aliquot was five-times diluted with the sterilized PBS (pH 7.5) solution and heated for 15 min at 95 °C (in a Stuart block heater) to release the miRNAs from microparticles and exosomes.18 Subsequently, a 10 μL aliquot of the diluted and heated sample was cast onto HS-DNA/AuNPs/SPCEs and the protocol described in Section 4.4 for the synthetic target miRNA was followed.

Cell culture and RNA extraction were performed following protocols described previously.29,30 The quality and concentration of the extracted RNA were confirmed by measuring the absorbance at appropriate wavelengths.

Table 3. DNA and RNA Used Synthetic Oligonucleotides

| oligonucleotide                  | sequence (5\' → 3\')                     |
|----------------------------------|-----------------------------------------|
| HS-capture DNA probe (HS-DNA)    | ACATCGATCTGATAGCTA-[thiol-C6]           |
| HS-capture RNA probe (HS-RNA)    | ACAUCAGUCUGAAAGCUCU-[Tthiol-C6]         |
| target miRNA-21                  | UAGCUUAUCAGACUGAU                     |
| 1-mismatched miRNA-21 (1-m)     | UAGCUUAAGACUGAU                   |
| miRNA-451 (NC)                   | UUGAGCUAUACCAUGGAAA                   |
| ProtA-polyHRP40, 1/500 and 1/25 diluted, respectively. This mixture solution, prepared in blocker casein solution, was preincubated for 30 min in an incubator shaker (30 °C, 950 rpm). The modified bioelectrodes were rinsed with sterilized water and dried with nitrogen. To prevent miRNA degradation by RNases, all manipulations, except the amperometric measurements, were made in a laminar flow cabinet. |
AKNOWLEDGMENTS

University of Tunis El Manar is acknowledged for the mobility grant (Bourse d’Alternance) awarded to M.Z. The financial support from the Spanish Ministerio de Economía y Competitividad Research Project (CTQ2015-64402-C2-1-R) and the NANOAVANSENS Program from the Comunidad de Madrid (S2013/MT-3029) are gratefully acknowledged. The authors also thank Drs. J.M. Sánchez-Puelles and E. López-Hernández for kindly providing us the RNA samples extracted from cell lines and Prof. Besma Loueslati for the blood serum samples. They also acknowledge Dropens S.L. company for SEM characterization of the working electrodes.

REFERENCES

(1) Cai, H.; Xu, C.; He, P.; Fang, Y. Colloid Au-enhanced DNA immobilization for the electrochemical detection of sequence-specific DNA. J. Electroanal. Chem. 2001, 510, 78–85.
(2) Kang, J.; Li, X.; Wu, G.; Wang, Z.; Lu, X. A new scheme of hybridization based on the Aunanno—DNA modified glassy carbon electrode. Anal. Biochem. 2007, 364, 165–170.
(3) Saha, K.; Agasti, S. S.; Kim, C.; Li, X.; Rotello, V. M. Gold nanoparticles in chemical and biological sensing. Chem. Rev. 2012, 112, 2739–2779.
(4) Zouari, M.; Campuzano, S.; Pingarrón, J. M.; Raouafi, N. Ultra-sensitive determination of microribonucleic acids in cancer cells with nanostructured-disposable electrodes using the viral protein p19 for recognition of ribonucleic acid/microribonucleic acid homoduplexes. Electrochim. Acta 2018, 262, 39–47.
(5) Felekissi, K.; Touvana, E.; Stefanou, C. H.; Deltas, C. MicroRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia 2010, 14, 236–240.
(6) Ramman, P.; Gao, Y.; Ozsoz, M.; Mulchandani, A. Electronic detection of microRNA at attomolar level with high specificity. Anal. Chem. 2013, 85, 8061–8064.
(7) Esquela-Kerscher, A.; Slack, F. J. Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259–269.
(8) Lan, H.; Lu, H.; Wang, X.; Jin, H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. BioMed Res. Int. 2015, 2015, No. 125094.
(9) Válozí, A.; Hornyik, C.; Varga, N.; Burgán, J.; Kauppinen, S.; Havelda, Z. Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res. 2004, 32, No. e175.
(10) Pall, G. S.; Codony-Servat, Ó.; Byrne, J.; Ritchie, L.; Hamilton, A. Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA, and piRNA by northern blot. Nucleic Acids Res. 2007, 35, No. e60.
(11) Chen, C.; Kidzon, D. A.; Broomer, A. J.; Zhou, Z.; Lee, D. H.; Nguyen, J. T.; Barbins, M. X.; Xu, N. L.; Mahuvakar, V. R.; Andersen, M. R.; Lao, K.; Qz, Livak, K. J.; Guegler, K. J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33, No. e179.
(12) Li, J.; Yao, B.; Huang, H.; Wang, Z.; Sun, C.; Fan, Y.; Chang, Q.; Li, S.; Wang, X.; Xi, J. Real-time polymerase chain reaction microRNA detection based on enzymatic stem-loop probes ligation. Anal. Chem. 2009, 81, 5446–5451.
(13) Kroh, E. M.; Parkin, R. K.; Mitchell, P. S.; Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50, 298–301.
(14) Thomson, J. M.; Parker, J.; Perou, C. M.; Hammond, S. M. A custom microarray platform for analysis of microRNA gene expression. Nat. Methods 2004, 1, 47–53.
(15) Nelson, P. T.; Baldwin, D. A.; Searce, L. M.; Oberholtzer, J. C.; Tobias, J. W.; Mourelatos, Z. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat. Methods 2004, 1, 155–161.
(16) Liang, R.; Q.; Li, W.; Li, Y.; Tan, C. Y.; Li, J. X.; Jin, Y. X.; Ruan, K. C. An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe. Nucleic Acids Res. 2005, 33, No. e17.
(17) Git, A.; Dringe, H.; Salmon-Divon, M.; Osborne, M.; Kutter, C.; Hadfield, J.; Bertone, P.; Caldas, C. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010, 16, 991–1006.
(18) Libib, M.; Khan, N.; Ghobadloo, S. M.; Cheng, J.; Pezacki, J. P.; Berezovski, M. V. Three-mode electrochemical sensing of ultralow microRNA levels. J. Am. Chem. Soc. 2013, 135, 3027–3038.
(19) Tran, H. V.; Piro, B.; Reisberg, S.; Duc, H. T.; Pham, M. C. Antibodies directed to RNA/DNA hybrids: an electrochemical immunosensor for microRNAs detection using graphene-composite electrodes. Anal. Chem. 2013, 85, 8469–8474.
(20) Tran, H. V.; Piro, B.; Reisberg, S.; Nguyen, L. H.; Nguyen, T. D.; Duc, H. T.; Pham, M. C. An electrochemical ELISA-like immunosensor for miRNAs detection based on screen-printed gold electrodes modified with reduced graphene oxide and carbon nanotubes. Biosens. Bioelectron. 2014, 62, 25–30.
(21) Wang, M.; Li, B.; Zhou, Q.; Yin, H.; Zhou, Y.; Ai, S. Label-free, ultrasensitive and electrochemical immunosensing platform for microRNA detection using anti-DNA/RNA hybrid antibody and enzymatic signal amplification. Electrochim. Acta 2015, 165, 130–135.
(22) Zouari, M.; Campuzano, S.; Pingarrón, J. M.; Raouafi, N. Competitive RNA-RNA hybridization-based integrated nanostructured-disposable electrode for highly sensitive determination of miRNAs in cancer cells. Biosens. Bioelectron. 2017, 91, 40–45.
(23) Torrente-Rodríguez, R. M.; Montiel, V. R.-V.; Campuzano, S.; Farchado-Dinia, M.; Barderas, R.; Segundo-Acosta, P. S.; Montoya, J. J.; Pingarrón, J. M. Fast electrochemical miRNAs determination in cancer cells and tumor tissues with antibody-functionalized magnetic microcarriers. ACS Sens. 2016, 1, 896–903.
(24) Torrente-Rodríguez, R. M.; Campuzano, S.; Montiel, V. R.-V.; Montoya, J. J.; Pingarrón, J. M. Sensitive electrochemical determination of miRNAs based on a sandwich assay onto magnetic microcarriers and hybridization chain reaction amplification. Biosens. Bioelectron. 2016, 86, 516–521.
(25) Torrente-Rodríguez, R. M.; Campuzano, S.; Montiel, V. R.-V.; Sagrera, A.; Domínguez-Cañete, J. J.; Granados, R.; Sánchez-Puelles, J. M.; Pingarrón, J. M. Electrochemical miRNAs determination in formalin-fixed, paraffin-embedded breast tumor tissues association with HER2 expression. JSM Biotechnol. Biom. 2016, 3, 1064.
(26) Vargas, E.; Torrente-Rodríguez, R. M.; Montiel, V. R.-V.; Povedano, E.; Pedrero, M.; Montoya, J. J.; Campuzano, S.; Pingarrón, J. M. Magnetic beads-based sensor with tailored sensitivity for rapid and single-step amperometric determination of miRNAs. Int. J. Mol. Sci. 2017, 18, 2151.
(27) Vargas, E.; Povedano, E.; Montiel, V. R. V.; Torrente-Rodríguez, R. M.; Zouari, M.; Montoya, J. J.; Raouafi, N.; Campuzano, S.; Pingarrón, J. M. Single-Step Incubation Determination of miRNAs in Cancer Cells Using an Amperometric Biosensor Based on Competitive Hybridization onto Magnetic Beads. Sensors 2018, 18, 863.
(28) Kilic, T.; Topkaya, S. N.; Ozsoz, M. A new insight into electrochemical microRNA detection: a molecular caliper, p19 protein. Biosens. Bioelectron. 2013, 48, 165–171.
(29) Campuzano, S.; Torrente-Rodríguez, R. M.; López-Hernández, E.; Conenzuelo, F.; Granados, R.; Sánchez-Puelles, J. M.; Pingarrón, J. M. Magnetobiosensors based on viral protein p19 for microRNA determination in cancer cells and tissues. Angew. Chem. Int. Ed. 2014, 81, 6168–6171.
(30) Torrente-Rodríguez, R. M.; Campuzano, S.; López-Hernández, E.; Granados, R.; Sánchez-Puelles, J. M.; Pingarrón, J. M. Direct immobilization of the working electrodes. Notes

The authors declare no competing financial interest.
determination of miR-21 in total RNA extracted from breast cancer samples using magneto sensing platforms and the p19 viral protein as detector bioreceptor. *Electroanalysis* **2014**, *26*, 2080–2087.

(31) Li, C.; Liu, Z.; Cai, S.; Wen, F.; Wu, D.; Liu, Y.; Wu, F.; Lan, J.; Han, Z.; Chen, J. An electrochemical microRNA biosensor based on protein p19 combining an acridone derivate as indicator and DNA concatamers for signal amplification. *Electrochem. Commun.* **2015**, *60*, 185–189.

(32) Cissell, K. A.; Rahimi, Y.; Shrestha, S.; Hunt, E. A.; Deo, S. K. Bioluminescence-based detection of microRNA, miR21 in breast cancer cells. *Anal. Chem.* **2008**, *80*, 2319–2325.

(33) Boguslawski, S. J.; Smith, D. E.; Michalak, M. A.; Mickelson, K.; Yehle, C. O.; Patterson, W. L.; Carrico, R. J. Characterization of monoclonal antibody to DNA.RNA and its application to immunodetection of hybrids. *J. Immunol. Methods* **1986**, *89*, 123–130.

(34) Hu, Z.; Zhang, A.; Storz, G.; Gottesman, S.; Leppla, S. H. An antibody-based microarray assay for small RNA detection. *Nucleic Acids Res.* **2006**, *34*, No. e52.

(35) Phillips, D. D.; Garboczi, D. N.; Singh, K.; Hu, Z.; Leppla, S. H.; Leynath, C. E. The sub-nanomolar binding of DNA-RNA hybrids by the single-chain Fv fragment of antibody S9.6. *J. Mol. Recognit.* **2013**, *26*, 376–381.

(36) Eguilaz, M.; Moreno-Guzmán, M.; Campuzano, S.; González-Cortes, A.; Yáñez-Sedeño, P.; Pingarrón, J. M. An electrochemical immunosensor for testosterone using functionalized magnetic beads and screen-printed carbon electrodes. *Biosens. Bioelectron.* **2010**, *26*, 517–522.

(37) Conzuelo, F.; Gamella, M.; Campuzano, S.; Reviejo, A. J.; Pingarrón, J. M. Disposable amperometric magneto-immunosensor for direct detection of tetracyclines antibiotics residues in milk. *Anal. Chim. Acta* **2012**, *737*, 29–36.

(38) Gamella, M.; Campuzano, S.; Conzuelo, F.; Reviejo, A. J.; Pingarrón, J. M. Amperometric magnetoimmunosensor for direct determination of D-dimer in human serum. *Electroanalysis* **2012**, *24*, 2235–2243.

(39) Degliangeli, F.; Pompa, P. P.; Fiammengo, R. Nanotechnology-based strategies for the detection and quantification of microRNA. *Chem. – Eur. J.* **2014**, *20*, 9476–9492.

(40) Wang, G.; Wang, L.; Sun, S.; Wu, J.; Wang, Q. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females. *Ann. Lab. Med.* **2015**, *35*, 226–232.

(41) Liu, L.; Xu, Q.; Hao, S.; Chen, Y. A quasi-direct LC-MS/MS-targeted proteomics approach for miRNA quantification via covalently immobilized DNA-peptide probe. *Sci. Rep.* **2017**, *7*, No. 5669.

(42) Yan, L. X.; Huang, X. F.; Shao, Q.; Huang, M. Y.; Deng, L.; Wu, Q. L.; Zeng, Y. X.; Shao, J. Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA* **2008**, *14*, 2348–2360.

(43) Xu, F.; Yang, T.; Chen, Y. Quantification of microRNA by DNA-peptide probe and liquid chromatography-tandem mass spectrometry-based quasi-targeted proteomics. *Anal. Chem.* **2016**, *88*, 754–763.

(44) Zhang, Y.; Yan, Y.; Chen, W.; Cheng, W.; Li, S.; Ding, X.; Li, D.; Wang, H.; Ju, H.; Ding, S. A simple electrochemical biosensor for highly sensitive and specific detection of microRNA based on mismatched catalytic hairpin assembly. *Biosens. Bioelectron.* **2015**, *68*, 343–349.